Copyright 2014 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
To the Editor We are concerned that the study by Dr Vigen and colleagues1 has serious flaws in both design and interpretation.
First, Vigen et al1 characterized testosterone treatment as filling a single prescription for any testosterone product and “once initiated, a patient was assumed to have continued treatment ….” This is insufficient for a definition of long-term testosterone therapy, especially when 17.6% received only 1 prescription. Moreover, there were no data on whether patients continued to regularly receive treatment.
Jones TH, Channer KS. Deaths and Cardiovascular Events in Men Receiving Testosterone. JAMA. 2014;311(9):962-963. doi:10.1001/jama.2014.398